Shareholders Approve Hanmi Pharmaceutical Acquisition with Strong Majority
APTOF has more than doubled off its 52-week low of $0.636 on elevated volume (2.5× avg).
Summary
Aptose Biosciences shareholders overwhelmingly approved the acquisition by Hanmi Pharmaceutical, with 84.87% voting in favor of the arrangement resolution.
Key Events · M&A and Partnerships · APTOF
-
Acquisition Approved
Shareholders voted 84.87% in favor of the plan of arrangement for HS North America Ltd. (a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd.) to acquire all outstanding common shares not currently owned by the Hanmi Purchasers.
-
Corporate Continuance Resolution
Shareholders also approved the continuance of the Corporation from the Canada Business Corporations Act to the Business Corporations Act (Alberta) with 92.42% of votes for.
Analysis · APTOF · Life Sciences
This 8-K details the shareholder vote results for the previously announced acquisition by Hanmi Pharmaceutical. The strong approval (84.87% of votes cast) confirms the transaction, providing a clear path forward for the company. This follows earlier recommendations from proxy advisory firms and concurrent court approval, solidifying the acquisition as a positive resolution for the financially distressed company.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APTOF was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.64 to $4.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.